Literature DB >> 16101537

The role of CXCR2/CXCR2 ligands in acute lung injury.

Robert M Strieter1, Michael P Keane, Marie D Burdick, Ammar Sakkour, Lynne A Murray, John A Belperio.   

Abstract

The mortality of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) remain high despite advances in our knowledge and intensive care. This supports the contention that we need to further our understanding of the mediators that are involved in the pathogenesis of ARDS. The pathogenesis of ARDS proceeds as a continuum from exudation and inflammation to a fibroproliferative phase of diffuse alveolar damage. While a number of mediators are involved in the pathogenesis of ARDS, members of the CXC chemokine family have been determined to play a critical and pleiotropic role in promoting both recruitment of inflammatory cells, as well as in mediating aberrant vascular remodeling during both phases of ARDS. The importance of the biology of CXC chemokines in ALI/ARDS will be discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101537     DOI: 10.2174/1568010054022178

Source DB:  PubMed          Journal:  Curr Drug Targets Inflamm Allergy        ISSN: 1568-010X


  18 in total

1.  Chemokine CXCL1-Mediated Neutrophil Trafficking in the Lung: Role of CXCR2 Activation.

Authors:  Kirti V Sawant; Renling Xu; Robert Cox; Hal Hawkins; Elena Sbrana; Deepthi Kolli; Roberto P Garofalo; Krishna Rajarathnam
Journal:  J Innate Immun       Date:  2015-07-01       Impact factor: 7.349

2.  Kinetics of chemokine-glycosaminoglycan interactions control neutrophil migration into the airspaces of the lungs.

Authors:  Yoshi Tanino; Deirdre R Coombe; Sean E Gill; Warren C Kett; Osamu Kajikawa; Amanda E I Proudfoot; Timothy N C Wells; William C Parks; Thomas N Wight; Thomas R Martin; Charles W Frevert
Journal:  J Immunol       Date:  2010-02-01       Impact factor: 5.422

Review 3.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

4.  Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice.

Authors:  A Zarbock; M Allegretti; K Ley
Journal:  Br J Pharmacol       Date:  2008-06-30       Impact factor: 8.739

Review 5.  Opening the flood-gates: how neutrophil-endothelial interactions regulate permeability.

Authors:  Matthew R DiStasi; Klaus Ley
Journal:  Trends Immunol       Date:  2009-09-23       Impact factor: 16.687

6.  Improved survival and reduced vascular permeability by eliminating or blocking 12/15-lipoxygenase in mouse models of acute lung injury (ALI).

Authors:  Alexander Zarbock; Matthew R Distasi; Emily Smith; John M Sanders; Gerhard Kronke; Brian L Harry; Sibylle von Vietinghoff; Konrad Buscher; Jerry L Nadler; Klaus Ley
Journal:  J Immunol       Date:  2009-09-14       Impact factor: 5.422

7.  A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis.

Authors:  Glenda Trujillo; Erica C O'Connor; Steven L Kunkel; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

8.  CXCR2 signaling and host defense following coronavirus-induced encephalomyelitis.

Authors:  Brett S Marro; Martin P Hosking; Thomas E Lane
Journal:  Future Virol       Date:  2012-04       Impact factor: 1.831

9.  CXCR2: From Bench to Bedside.

Authors:  Anika Stadtmann; Alexander Zarbock
Journal:  Front Immunol       Date:  2012-08-24       Impact factor: 7.561

10.  A protective role for ELR+ chemokines during acute viral encephalomyelitis.

Authors:  Martin P Hosking; Liping Liu; Richard M Ransohoff; Thomas E Lane
Journal:  PLoS Pathog       Date:  2009-11-06       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.